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Abstract Ciliary neurotrophic factor (CNTF) is a member of
the gp130 family of cytokines. The functional receptor complex
of CNTF is composed of the CNTF receptor K (CNTFR), gp130
and the leukemia inhibitory factor receptor (LIFR). Three
regions on CNTF have been identified as binding sites for its
receptors. The ligand^receptor interactions are mediated through
the cytokine binding domains (CBDs) and/or the immunoglobu-
lin-like domains of the receptors. However, in the case of CNTF,
the precise nature of the protein^protein contacts in the signaling
complex has not yet been resolved. In this study, we provide the
first demonstration that the membrane distal CBD (CBD1) of
LIFR associates in vitro with soluble CNTFR in the absence of
CNTF. Moreover, purified CBD1 partially blocks CNTF
signaling, but not that of interleukin-6 or LIF, in human
embryonal carcinoma cell line Ntera/D1 cells. These data raise
the possibility that LIFR has the capability to form a ligand-free
complex with CNTFR. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Ciliary neurotrophic factor (CNTF) belongs to the gp130
cytokine family which includes leukemia inhibitory factor
(LIF), interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin
M (OSM), cardiotrophin-1 (CT-1) [1,2] and cardiotrophin-like
cytokine (CLC) [3,4]. All these cytokines use gp130 as one of
their signal-transducing subunits, and CNTF, LIF, OSM,
CLC and CT-1 also use the LIF receptor (LIFR) as another
signaling molecule in their receptor complexes. IL-6, IL-11,
and CNTF must ¢rst bind to their speci¢c, non-signaling K-
receptors before they can subsequently induce the dimeriza-
tion of signaling receptor subunits.
CNTF receptor (CNTFR) is anchored to the cell membrane
through a glycosylphosphatidylinositol linkage [5] ; however,
soluble CNTFR (sCNTFR) can also be detected under nor-
mal physiological conditions [6]. Association of CNTF with
CNTFR leads to the heterodimerization of gp130 and LIFR
followed by the activation of pre-associated Janus kinases
(JAK1, JAK2, TYK2) [7,8]. Tyrosine-phosphorylated gp130
and LIFR in turn act as docking sites for the signal trans-
ducer and activator of transcription (STAT) molecules, such
as STAT3 [9]. After tyrosine phosphorylation, STAT3 forms a
homodimer, translocates into the nucleus and regulates the
expression of CNTF responsive genes.
CNTFR, gp130 and LIFR belong to the class I hemato-
poietin receptor family, which is characterized by the cytokine
binding domain (CBD) formed by two ¢bronectin type III
(FnIII) modules linked by a proline-rich sequence [10]. The
N-terminal module of the CBD contains four conserved cys-
teine residues that form inter-strand disul¢de bonds, while the
C-terminal module contains the WSXWS sequence conserved
in the hematopoietin receptors. The extracellular region of
CNTFR contains an N-terminal immunoglobulin (Ig)-like
module and a CBD, while that of LIFR contains an N-ter-
minal CBD (CBD1) followed by an Ig-like module, a C-ter-
minal CBD (CBD2) and three membrane-proximal FnIII
modules (Fig. 1).
As more data emerged, tripartite receptors were identi¢ed
for IL-6 and CNTF, suggesting a tetrameric complex, and
mutagenesis studies identi¢ed three binding sites on the
gp130 family cytokines [11]. The crystal structure of CNTF
has been solved revealing a four helix bundle and giving the
location of the three sites (I, II and III) which are responsible
for the binding of CNTFR, gp130 and LIFR [12,13]. How-
ever, the precise nature of receptor^receptor interactions in
the CNTFR complex remains unclear.
To shed further light on the receptor^receptor interactions
involved in CNTF signaling, a variety of domains from LIFR
were expressed and assessed for interactions with sCNTFR.
We report here that CBD1 of LIFR can bind to sCNTFR in
the absence of CNTF. More importantly, puri¢ed LIFR
CBD1 partially blocked CNTF signaling in human embryonal
carcinoma cell line Ntera/D1 (NT-2) cells.
2. Materials and methods
2.1. Cells and reagents
Human NT-2 embryonal carcinoma cells (Stratagene) were rou-
tinely grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM), sup-
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plemented with 10% fetal bovine serum. Human CNTF was from
RpD Systems. Human LIF was the product of Upstate Biotechnol-
ogy and IL-6 was from Invitrogen. Polyclonal goat anti-CNTF and
-LIFR antibodies were purchased from RpD Systems, while antibod-
ies detecting phospho-tyrosine STAT3 (Tyr 705) and STAT3 were
from New England Biolabs. Monoclonal anti-c-myc antibody was
the product of Calbiochem.
2.2. Construction of bacterial expression vectors for sCNTFR-myc,
CNTF and domains within the extracellular regions of LIFR
cDNA templates encoding the full length human CNTFR and rat
CNTF were reverse transcription (RT-) PCR-ampli¢ed from mRNAs
of NT-2 human embryonal carcinoma cells and rat pheochromocyto-
ma PC12 cells, respectively. Human LIFR cDNA template was RT-
PCR-ampli¢ed from mRNA of SH-SY5Y human neuroblastoma
cells. DNA sequencing was performed using a 310 Genetic Analyzer
autosequencer (Applied Biosystems). DNA sequences were checked
against the sequences in the GenBank database. The bacterial expres-
sion vector for His-tag proteins was based on pET-14b (Novagen)
with slight modi¢cations. The NcoI site at 580 was changed to an
NdeI site and the NdeI site at 522 was mutated to an NcoI site and
a new NotI site was inserted after the BamHI site at 510. NcoI and
NotI sites were introduced in the 5P- and 3P-primers for PCR ampli-
¢cation of all the constructs. Ampli¢ed PCR products were digested
with NcoI and NotI restriction enzymes and subcloned into the modi-
¢ed pET-14b vector. Expressed peptides after N-terminal His-tag la-
beling were: sCNTFR-myc (M1^I334 followed by a c-myc epitope
EQKLSEEDL), full length rat CNTF, CBD1 of LIFR (D52^S239),
Ig-like domain of LIFR (P240^N340), CBD2 of LIFR (C341^S523),
CBD1-Ig of LIFR (D52^N340), Ig-CBD2 of LIFR (P240^S523), and
CBD1-Ig-CBD2 of LIFR (Q45^S523).
2.3. Protein expression, puri¢cation and refolding
Escherichia coli bacteria (strain BL21 (DE3)) were transformed with
expression vectors containing cDNAs for sCNTFR-myc, rat CNTF
and individual domains of LIFR. Transformed bacteria were grown
to an A600 of approximately 0.2 at 37‡C and induced by 1 mM iso-
propyl-1-thio-L-D-galactopyranoside (IPTG) for 4 h. For the puri¢ca-
tion of sCNTFR-myc, rat CNTF, CBD1 of LIFR, inclusion bodies
were denatured in 8 M urea, pH 8.0. After binding to a Ni-NTA
column (Qiagen), His-tagged peptides were eluted by 8 M urea, pH
4.5. Refolding of sCNTFR-myc was as previously described [13], and
refolding of other proteins was achieved by dialysis against refolding
bu¡er (10 mM Tris, pH 8.0, 1 mM reduced glutathione, 0.1 mM
oxidized glutathione, 36 h). Refolded proteins were loaded on a Q
Sepharose High Performance column (Pharmacia) and eluted with a
salt gradient using an Akta explorer 100 FPLC puri¢cation system
(Pharmacia).
2.4. Enzyme-linked immunosorbent assay (ELISA) for sCNTFR
binding
Puri¢ed CNTFR-myc was coated on Immulon02 (Dynatech) ELI-
SA plates at 10 Wg/ml. After blocking of non-speci¢c binding with
phosphate-bu¡ered saline (PBS) containing 0.25% bovine serum albu-
min (BSA), puri¢ed peptides with serial dilutions in PBS^0.2 Wg/Wl
BSA were applied. For the screening of binding capability of LIFR
domains, 10 Wg of the supernatants of IPTG-induced bacterial lysates
after sonication was added to the wells. After incubation and washing,
bound proteins were detected with speci¢c antibodies at 1:2000 dilu-
tions followed by horseradish peroxidase (HRP)-conjugated second-
ary antibodies with the same dilutions. Peroxidase activity was de-
tected by o-phenylenediamine substrate and the orange-colored
product was read at 490 nm using a MR 5000 microplate reader
(Dynatech).
2.5. Immunoprecipitation and Western blotting for CBD1-sCNTFR pull
down assay
200 ng of puri¢ed CBD1 was incubated with 200 ng of puri¢ed
sCNTFR-myc, 1 Wg anti-myc antibody and 10 Wg BSA in 200 Wl
PBS overnight at 4‡C. 10 Wl kappa-lock (Zymed) beads were added.
After 2 h incubation, beads were washed with PBS and 20 Wl 2Usam-
ple bu¡er for SDS^PAGE was added. The boiled supernatants were
collected, separated by SDS^PAGE and blotted onto nitrocellulose
membranes. After blocking in TBST containing 5% milk powder,
membranes were incubated with primary antibodies in 1:1000 dilu-
tions at 25‡C for 1 h. Membranes were incubated with HRP-conju-
gated secondary antibodies with 1:2000 dilutions for another 1 h after
washing with TBST. Proteins were detected by chemiluminescence
using an ECL kit (Amersham) following the manufacturer’s instruc-
tions.
2.6. STAT3 phosphorylation assay
NT-2 cells were starved for 4 h in the serum-free DMEM culture
medium, without antibiotics, but containing di¡erent concentrations
of puri¢ed CBD1 peptide, before stimulation with cytokines. After
starvation, 50 ng/ml cytokines were applied and cells were incubated
at 37‡C for 15 min. Cells were lysed in RIPA bu¡er with protease
inhibitors (PBS with 0.1% SDS, 1% NP40, 0.5% deoxycholic acid, 10
Wg/ml leupeptin, 10 Wg/ml aprotinin, 2 Wg/ml antipain, 5 mM benza-
midine, 1 mM sodium orthovanadate, 10 Wg/ml soybean trypsin in-
hibitor and 1 mM phenylmethylsulfonyl £uoride, Sigma) and insolu-
ble material was pelleted. Protein concentrations of supernatants were
assayed by the Bradford method (Bio-Rad). 50 Wg of total cell lysates
was subjected to SDS^PAGE followed by Western blotting using an
anti-phospho-tyrosine STAT3 antibody. After stripping of mem-
branes using bu¡er containing 0.1 M L-mercaptoethanol, 0.0625 M
Tris, pH 6.7 and 2% SDS, an anti-STAT3 antibody was used for the
detection of total STAT3 expression. Band intensity was analyzed
using the Eagle Eye II Still Video System (Stratagene).
3. Results
3.1. Screening of putative binding modules within extracellular
regions of LIFR with sCNTFR
To assess the binding capacity of sCNTFR to the individ-
ual domains within the extracellular parts of LIFR in the
absence of ligand, we set up an ELISA system for the rapid
screening of the receptor domains (Fig. 2). sCNTFR was
tagged with a c-myc epitope at the carboxyl-terminus, and a
Fig. 1. Schematic representation of the LIFR domain mutants that were used in this study. CBD1, Ig, CBD2, CBD1-Ig, Ig-CBD2 and CBD1-
Ig-CBD2 regions of LIFR were expressed as His-tagged peptides in E. coli as described in Section 2. The conserved cysteines and the WSXWS
motif in the CBDs of LIFR are shown as vertical thin lines and black bars, respectively.
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polyhistidine epitope at the N-terminus for ease of puri¢ca-
tion (Fig. 2A). Puri¢ed sCNTFR-myc retained the capacity
to bind to puri¢ed His-CNTF as shown by immuno-
precipitation (Fig. 2B). Puri¢ed sCNTFR-myc (10 Wg/ml)
was directly coated onto an ELISA plate and as low as
0.025 Wg/ml CNTF could be detected using this system (Fig.
2C).
We screened for the putative binding modules within the
extracellular domains of LIFR using sCNTFR. The individual
domain constructs included CBD1, Ig, CBD2, CBD1-Ig, Ig-
CBD2 and CBD1-Ig-CBD2 of LIFR. These domains were
expressed as N-terminal His-tagged peptides in E. coli. After
IPTG induction followed by sonication, supernatants of bac-
terial lysates with equal amounts of total protein were sub-
jected to Western blotting and ELISA assays. While most of
the peptides could be detected by Western blot in both the
supernatants (Fig. 3A) and pellets (data not shown) after son-
ication, the CBD1-Ig module of LIFR could only be detected
in the pellets (data not shown). ELISA screening showed that
the CBD1 and CBD1-Ig-CBD2 of LIFR could bind to
sCNTFR (Fig. 3B). These results strongly suggested that the
CBD1 of LIFR was responsible for the binding with
sCNTFR.
3.2. In vitro binding of sCNTFR with CBD1 of LIFR
To further con¢rm the binding capacity of sCNTFR with
CBD1 of LIFR, we performed an in vitro pull down assay.
LIFR CBD1 was expressed as a His-tagged protein, refolded
and puri¢ed as described under Section 2 (Fig. 4A). The far-
UV circular dichroism spectrum of puri¢ed CBD1 was con-
sistent with the published spectra of peptides with a similar
secondary structure [14,15] (data not shown). LIFR CBD1
could be pulled down by sCNTFR-myc with an anti-myc anti-
body (Fig. 4B). As low as 0.125 Wg/ml of LIFR CBD1 could
be detected using ELISA (Fig. 4C) with sensitivity comparable
to that of CNTF binding.
Fig. 2. Establishment of an ELISA system for screening binding partners of CNTFR. sCNTFR-myc and His-CNTF were puri¢ed to more
than 90% homogeneity as shown by SDS^PAGE followed by Coomassie blue staining and Western blot (A). sCNTFR-myc could be immuno-
precipitated with an anti-myc antibody and retained the capability to bind to His-CNTF (B). Binding of His-CNTF to the ELISA plate coated
with sCNTFR-myc (10 Wg/ml) was speci¢c and dose dependent (C). Results shown represent the mean þ S.D. of a typical experiment, n = 4.
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3.3. Blocking of CNTF signaling in NT-2 cells by CBD1 of
LIFR
As CBD1 of LIFR could bind to sCNTFR in vitro, we
investigated whether this peptide could serve as an antagonist
to block CNTF signaling in vivo. We chose NT-2 human
embryonal carcinoma cells [16] as the assay system, as these
cells had endogenous expression of CNTFR, LIFR and gp130
(Ip, N.Y. et al., unpublished observation). NT-2 cells could
respond to CNTF stimulation by rapid STAT3 tyrosine phos-
phorylation. We ¢rst examined the in vivo interaction between
CNTFR and LIFR in NT-2 cells. Immunoprecipitation of
total NT-2 cell lysate with an anti-CNTFR antibody could
pull down LIFR in the presence or absence of exogenous
CNTF (Fig. 5A). Addition of LIFR CBD1 (1 Wg/ml) could
partially block CNTF signaling by V50% (Fig. 5B,C). IL-6
and LIF signaling were not inhibited, but were enhanced in
the presence of LIFR CBD1 (Fig. 5B,C).
4. Discussion
Previous study [17] has suggested CNTF forms a hexameric
signaling complex. To explain this complex, a model was pro-
posed whereby the Ig-like domain of gp130 bridged two
growth hormone style trimers of speci¢c receptor, ligand
and the CBD of gp130 [18]. However, a tetrameric model
has been proposed which postulates that the hexamer is an
inactive state of the receptor complex, which forms at high
concentrations from the active tetramer induced by ligand
binding [19]. As LIFR is highly modular (Fig. 1), the di¡erent
modules in this receptor are likely to have varying roles in the
interaction with CNTF and CNTFR. To examine the impor-
tance of di¡erent receptor regions of LIFR in the CNTF
signaling complex, we constructed a series of peptides contain-
ing all the combinations of LIFR domains likely to be in-
volved in the CNTFR^LIFR interaction.
A sCNTFR molecule with a c-myc epitope was used as a
Fig. 3. ELISA screening for putative binding partners, from within
LIFR, of sCNTFR. Individual mutants were expressed in BL21
(DE3) bacterial host cells. Cells were lysed by sonication after IPTG
induction. Supernatants of the lysates were collected and subjected
to SDS^PAGE followed by Western blot analysis using polyclonal
anti-LIFR antibody (A). The His-tagged CBD1-Ig of LIFR could
not be expressed as soluble protein. CBD1 and CBD1-Ig-CBD2 of
LIFR (B) were found to bind strongly to sCNTFR-myc-coated
plates. Bars show the mean þ S.D., n = 3.
Fig. 4. In vitro binding of CBD1 of LIFR with sCNTFR-myc.
CBD1 of LIFR was expressed as a His-tagged peptide and puri¢ed
to more than 90% homogeneity as shown by SDS^PAGE followed
by Coomassie blue staining and Western blotting using polyclonal
anti-LIFR antibodies (A). sCNTFR-myc could pull down the LIFR
CBD1 by immunoprecipitation with an anti-myc antibody (B). The
binding of the LIFR CBD1 to an sCNTFR-myc-coated ELISA
plate was dose dependent (C). Results shown represent the
mean þ S.D. of a typical experiment, n = 4.
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potential binding partner for the LIFR peptides. The correct
folding of sCNTFR was con¢rmed by its ability to bind to
CNTF as shown by immunoprecipitation and ELISA assays.
Of the ¢ve LIFR peptides examined only the peptides con-
taining CBD1 showed binding to sCNTFR, indicating that
CBD1 is likely to be the domain involved in the CNTFR^
LIFR interaction. Consequently, the LIFR CBD1 was se-
lected for further testing. It is possible that the peptides that
did not bind to sCNTFR were misfolded. However, in a study
of domains of LIFR [20], CBD2 of LIFR could be recovered
and recognized by an anti-CBD2 antibody while CBD1 or
CBD1-Ig could not be expressed. These data suggest that
proper expression and folding of LIFR CBD2 may be more
readily achieved than that of CBD1.
To further examine the role of the LIFR CBD1 in the
interaction with sCNTFR, the peptide was puri¢ed and as-
sayed by immunoprecipitation and ELISA. This con¢rmed
the binding of this peptide to the sCNTFR in the absence
of CNTF. Having established that a ligand-free interaction
can exist in vitro between sCNTFR and the LIFR CBD1,
we decided to test this peptide in vivo. NT-2 embryonal car-
cinoma cells which respond to CNTF stimulation by STAT3
tyrosine phosphorylation were used to assess the interaction
of the CBD1 with CNTFR. It was seen that the CNTF-in-
duced phosphorylation of STAT3 was reduced by V50% in
the presence of CBD1 of LIFR. This suggests that the soluble
CBD1 binds to the same site on CNTFR as the cellular LIFR,
blocking its association with CNTFR, and preventing the for-
mation of the signal-transducing complex. Interestingly, the
immunoprecipitation assay showed that cellular LIFR and
CNTFR can form a complex in quiescent NT-2 cells without
the addition of exogenous CNTF, raising the possibility that
CNTFR could also interact with LIFR in the absence of
CNTF in vivo. As we could not rule out the presence of a
trace amount of endogenous ligands in NT-2 cells, further
studies will be necessary to explore this interesting observa-
tion.
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Fig. 5. Blocking of CNTF signaling in NT-2 cells by CBD1 of
LIFR. Cellular CNTFR could associate with LIFR on the surface
of NT-2 cells (A). Total cell lysates were collected and immunopre-
cipitated with an anti-CNTFR antibody. Western blot was then
probed with an anti-LIFR antibody. The LIFR CBD1 (1 Wg/ml)
could block CNTF-induced STAT3 tyrosine phosphorylation in
NT-2 cells by V50% (B). LIF and IL-6 signaling were not inhib-
ited, but were enhanced in the presence of LIFR CBD1. Quantita-
tion of relative band intensity was shown as the mean þ S.E.M. of
three representative experiments (C). The values are normalized to
that observed with CNTF treatment (100). Similar results were ob-
tained by using di¡erent batches of puri¢ed peptide.
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